Expertise in
4
conditions

Dr. Mezgebe Berhe

Infectious Disease
North Texas Infectious Diseases Consultants
3409 Worth St, Suite 710, 
Dallas, TX 
Accepting New Patients
Offers Telehealth
Expertise in
4
conditions
North Texas Infectious Diseases Consultants
3409 Worth St, Suite 710, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mezgebe Berhe is an Infectious Disease provider in Dallas, Texas. Dr. Berhe is highly rated in 4 conditions, according to our data. His top areas of expertise are Osteomyelitis, Osteomyelitis in Children, HIV/AIDS, and Familial Chronic Mucocutaneous Candidiasis. Dr. Berhe is currently accepting new patients.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Licenses
Specialist in TX
Hospital Affiliations
Baylor University Medical Center
Languages Spoken
English
German
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
View 2 Less Insurance Carriers -

Locations

NORTH TEXAS INFECTIOUS DISEASES CONSULTANTS
3409 Worth St, Suite 710, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Drug
Study Drugs: GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir
Study Phase: Phase 2
A Phase 3 Study of the Safety of Trogarzo® Administered as an Undiluted IV Push Over a Reduced Interval or as an Intramuscular Injection in Clinically Stable HIV-1 Infected Trogarzo® Experienced Patients and Healthy HIV-uninfected Volunteers
A Phase 3 Study of the Safety of Trogarzo® Administered as an Undiluted IV Push Over a Reduced Interval or as an Intramuscular Injection in Clinically Stable HIV-1 Infected Trogarzo® Experienced Patients and Healthy HIV-uninfected Volunteers
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Ibalizumab-uiyk
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
Enrollment Status: Completed
Publish Date: October 21, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants
A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Biological
Study Drug: TMB-365
Study Phase: Phase 1
View 5 Less Clinical Trials

18 Total Publications

Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.
Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: June 04, 2025
Similar Doctors
David E. Greenberg
Expertise in
9
conditions
Dr. David E. Greenberg
Infectious Disease
Expertise in
9
conditions
Dr. David E. Greenberg
Infectious Disease

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (4.6 mi)
214-645-8300
Languages Spoken:
English

David Greenberg is an Infectious Disease provider in Dallas, Texas. Dr. Greenberg is highly rated in 9 conditions, according to our data. His top areas of expertise are Pneumonia, Strep Throat, COVID-19, and Pseudomonas Stutzeri Infections.

Expertise in
13
conditions
Dr. Cedric W. Spak
Infectious Disease
Expertise in
13
conditions
Dr. Cedric W. Spak
Infectious Disease

Texas Centers For Infectious Disease Associates PA

3410 Worth St, Suite 780, 
Dallas, TX 
 (0.1 mi)
817-810-9810
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Cedric Spak is an Infectious Disease provider in Dallas, Texas. Dr. Spak is highly rated in 13 conditions, according to our data. His top areas of expertise are Actinomycosis, Herpes Virus Antenatal Infection, Cytomegalic Inclusion Disease, and Osteomyelitis. Dr. Spak is currently accepting new patients.

Expertise in
2
conditions
Dr. Tawanda Gumbo
Infectious Disease
Expertise in
2
conditions
Dr. Tawanda Gumbo
Infectious Disease
Ut Southwestern Medical Ctr, 5323 Harry Hines Blvd, 
Dallas, TX 
 (3.9 mi)
214-648-9914
Languages Spoken:
English

Tawanda Gumbo is an Infectious Disease provider in Dallas, Texas. Dr. Gumbo is highly rated in 2 conditions, according to our data. Her top areas of expertise are Mycobacterium Avium Complex Infections, Disseminated Tuberculosis, Tuberculous Meningitis, and Bacterial Meningitis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Berhe's expertise for a condition
ConditionClose
      View All 29 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile